any patients with chronic obstructive airways disease (CGAD) do not develop polycythemia even though they have similar degree of hypoxia as normal high altitude dwellers and patients with cyanotic heart disease. I In an attempt to explain the lack of erythropoietic response to hypoxia in CGAD we evaluated the iron status in a group of CGAD patients. We chose serum ferritin measurement and the desferrioxamine test to evaluate iron status since liver biopsy was not justifiable.
Twenty patients suffering from CGAD (18 men and 2 women, aged 72 ± 10 years) and 10 age matched healthy subjects (8 men and 2 women aged 73 ± 7 y) were studied. Diagnosis of CGAD was based on detailed history and spirometric parameters, according to the American Thoracic Society recommendations. All patients had abnormal spirometry (FEY I IFYC < 651170 of the predicted values) and hypoxaemia (values were less than mean -2SD of the control group). Twelve patients were hypercapnic (pCG 2>6'13 kPa, a value established from results obtained in the control group). All studies were done when patients were in hospital and at a time when they were clinically free of acute infection. In none of the patients was there evidence of any other disease. At the time of study none of the patients was receiving any medication which might alter iron metabolism. All patients gave informed consent. None of the control subjects showed haematological problems or alterations of iron metabolism. All of them had normal respiratory function, as defined by clinical and spirometric methods. All samples were collected at 0900 h in order to avoid fluctuations due to circadian rhythm. Blood counts and red cell indices were measured by automated methods (Coulter Electronics UK). Serum and urine iron levels and the unsaturated iron binding capacity (UIBC) were determined by standard colorimetric methods (Sigma, Spain). Serum transferrin determinations were made by radial immunodiffusion technique (Accuplates' ). Ferritin was measured using a commercial ELISA assay (Abbott, UK). The d~sferrioxamine test was performed by measunng the 24-h urinary iron excretion before and after intramuscular administration of 500 mg of desferrioxamine. Results are given as means and standard deviations as all variables studied were distributed normally. Student's t test was used to compare groups.
The results are summarized in Table 1 . Haemoglobin and haematocrit values in CGAD patients were not significantly different from controls. However, red cell count was higher (P=O·03) and MCHC was lower (P=O·OI) in the CGAD group. This decrease in the MCHC has been attributed to an osmotic shift of water into the red blood cells.?
Serum indices of iron metabolism were similar in the two groups. However, urine iron excretion, under basal conditions (P=0·038) and after administration of desferrioxamine (P= 0'016) was significantly higher in the patient group. In the 12 hypercapnic patients urine iron excretion (28' 4 ± 18· 4 J.Lmo1/24 h) was significantly higher than in nonhypercapnic patients (7'6 ± 12·0 J.Lffiol/ 24 h n = 8 P= 0'021). Urine iron excretion after desferrioxamine administration was 52· 4 ± 22· 4 J.Lmo1124 h in hypercapnic patients and 40· 6 ± 26' 4 J.Lmo1124 h in non hypercapnic patients.
The higher urinary iron excretion in the hypercapnic patients suggest that acidosis or hypercapnia could be involved in this phenomenon. This interpretation has been indirectly reported by other authors in a model of renal ischaemia. 3 The considerable increase in the urinary excretion of iron after the administration of desferrioxamine in eOAD patients cannot be explained by iron overload since the iron stores of the patients with eOAD (assessed by serum ferritin) were similar to those of the control group. This phenomenon could be explained by the mechanism of action of desferrioxamine. Desferrioxamine chelates iron bound to low molecular weight cytoplasmic compounds." Hypoxia and acidosis are known to delocalize iron by releasing it from binding proteins; thereby increasing the amount of chelatable iron pool. 5 It is therefore possible that hypoxia and acidosis observed in respiratory insufficiency increase the chelatable pool and account for the elevated urinary iron elimination after the administration of desferrioxamine. Furthermore increased intestinal absorption of iron stimulated by hypoxia'' may contribute to the high iron excretion after desferrioxamine.
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Our observation that polycythemia is unusual in patients with respiratory insufficiency confirms previous reports;' Several factors could contribute to the absence of polycythemia, such as bronchial inflammation, and hypercapnia, which reduce the erythropoietic response. ' We suggest that, in addition to these factors, iron depletion due to elevated urinary elimination may also contribute to the reduced erythropoietic response in eOAD.
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